Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

727 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Impact of natalizumab on quality of life in a real-world cohort of patients with multiple sclerosis: Results from MS PATHS.
Hersh CM, Kieseier B, de Moor C, Miller DM, Campagnolo D, Williams JR, Fitzgerald KC, Xiong K, McGinley MP, Hyland M, Rudick RA, Ziemssen T, Koulinska I. Hersh CM, et al. Among authors: miller dm. Mult Scler J Exp Transl Clin. 2021 Apr 15;7(2):20552173211004634. doi: 10.1177/20552173211004634. eCollection 2021 Apr-Jun. Mult Scler J Exp Transl Clin. 2021. PMID: 33948221 Free PMC article.
Cognitive processing speed in multiple sclerosis clinical practice: association with patient-reported outcomes, employment and magnetic resonance imaging metrics.
Macaron G, Baldassari LE, Nakamura K, Rao SM, McGinley MP, Moss BP, Li H, Miller DM, Jones SE, Bermel RA, Cohen JA, Ontaneda D, Conway DS. Macaron G, et al. Among authors: miller dm. Eur J Neurol. 2020 Jul;27(7):1238-1249. doi: 10.1111/ene.14239. Epub 2020 May 1. Eur J Neurol. 2020. PMID: 32222019
Determining the effectiveness of early intensive versus escalation approaches for the treatment of relapsing-remitting multiple sclerosis: The DELIVER-MS study protocol.
Ontaneda D, Tallantyre EC, Raza PC, Planchon SM, Nakamura K, Miller D, Hersh C, Craner M, Bale C, Chaudhry B, Gunzler DD, Love TE, Gerry S, Coles A, Cohen JA, Evangelou N. Ontaneda D, et al. Contemp Clin Trials. 2020 Aug;95:106009. doi: 10.1016/j.cct.2020.106009. Epub 2020 Apr 19. Contemp Clin Trials. 2020. PMID: 32320842
Technology-enabled assessments to enhance multiple sclerosis clinical care and research.
Macaron G, Moss BP, Li H, Baldassari LE, Rao SM, Schindler D, Alberts JL, Weber M, Ayers M, Bethoux F, Boissy A, Chizmadia D, Conway DS, Fink C, Fox RJ, Gales S, Green B, Hara-Cleaver C, Jordan N, Mahajan KR, McGinley MP, Miller DM, Namey M, Rae-Grant A, Rensel M, Young H, Willis MA, Ontaneda D, Cohen JA, Bermel RA. Macaron G, et al. Among authors: miller dm. Neurol Clin Pract. 2020 Jun;10(3):222-231. doi: 10.1212/CPJ.0000000000000710. Neurol Clin Pract. 2020. PMID: 32642324 Free PMC article.
Multiple Sclerosis Performance Test: validation of self-administered neuroperformance modules.
Rao SM, Galioto R, Sokolowski M, McGinley M, Freiburger J, Weber M, Dey T, Mourany L, Schindler D, Reece C, Miller DM, Bethoux F, Bermel RA, Williams JR, Levitt N, Phillips GA, Rhodes JK, Alberts J, Rudick RA. Rao SM, et al. Among authors: miller dm. Eur J Neurol. 2020 May;27(5):878-886. doi: 10.1111/ene.14162. Epub 2020 Mar 2. Eur J Neurol. 2020. PMID: 32009276
Health-related quality of life in multiple sclerosis: effects of natalizumab.
Rudick RA, Miller D, Hass S, Hutchinson M, Calabresi PA, Confavreux C, Galetta SL, Giovannoni G, Havrdova E, Kappos L, Lublin FD, Miller DH, O'Connor PW, Phillips JT, Polman CH, Radue EW, Stuart WH, Wajgt A, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA; AFFIRM and SENTINEL Investigators. Rudick RA, et al. Ann Neurol. 2007 Oct;62(4):335-46. doi: 10.1002/ana.21163. Ann Neurol. 2007. PMID: 17696126 Clinical Trial.
727 results